Santhera Pharmaceuticals
Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of severe neuromuscular diseases, an area of high unmet medical needs.
Clinical Trials
Santhera is currently recruiting patients for clinical studies in
- Friedreich’s Ataxia in US and Europe
- Leber’s Hereditary Optic Neuropathy in Germany, UK and shortly in Canada
- Dyskinesia in Parkinson’s Disease in US
Development Programs
Santhera has three compounds in five clinical development programs: SNT-MC17 in Friedreich’s Ataxia, Duchenne Muscular Dystrophy and Leber’s Hereditary Optic Neuropathy, JP-1730 in Dyskinesia in Parkinson’s Disease and SNT-317 in Congenital Muscular Dystrophy
Latest News
May 28, 2008
Santhera Presents Efficacy Data of SNT-317 in Congenital Muscular Dystrophy at International Congress of Myology
April 21, 2008
Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting